Investment Bank Reiterates Buy Rating For Therapeutics Company

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and glioblastoma. $Black Diamond Therapeutics (BDTX.US)$